Farther Finance Advisors LLC Lowers Position in Natera, Inc. $NTRA

Farther Finance Advisors LLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 77.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 884 shares of the medical research company’s stock after selling 3,072 shares during the quarter. Farther Finance Advisors LLC’s holdings in Natera were worth $142,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in NTRA. Hilltop National Bank purchased a new stake in Natera during the second quarter worth $33,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Natera during the 2nd quarter worth about $36,000. Sound Income Strategies LLC boosted its stake in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Natera during the 2nd quarter valued at about $53,000. Finally, N.E.W. Advisory Services LLC increased its stake in shares of Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 226 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating and raised its price target to $270 (from $230), signalling stronger analyst conviction and a higher valuation anchor for NTRA. Guggenheim Sticks to Their Buy Rating for Natera (NTRA)
• Positive Sentiment: Natera entered a collaboration with Exelixis on the STELLAR-316 Phase 3 trial of zanzalintinib for colorectal cancer — a potential revenue and pipeline catalyst for Natera’s oncology offerings (Signatera MRD monitoring could benefit). Exelixis and Natera to Collaborate on STELLAR-316
• Positive Sentiment: Coverage of the Exelixis collaboration in other outlets is driving momentum for both stocks, highlighting clinical validation and near-term trial milestones that could lift demand for Natera’s oncology assays. Exelixis and Natera stocks rise on colorectal cancer trial collaboration
• Positive Sentiment: Natera launched a 21‑gene Fetal Focus™ single‑gene NIPT powered by its LinkedSNP™ technology, expanding reproductive‑health product breadth and potential revenue per test. Product launches can improve near‑term commercial outlook if adoption accelerates. Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT
• Neutral Sentiment: Broad market coverage and price tracking pieces summarize the stock’s move and analyst consensus; useful context but not direct catalysts. Natera (NTRA) share price
• Negative Sentiment: Significant insider selling has been reported: multiple executives and insiders (including CEO Steven Chapman and Solomon Moshkevich) recently sold shares; a report aggregates ~US$47M in insider sales—this can create investor caution or signal profit‑taking. Insiders At Natera Sold US$47m In Stock
• Negative Sentiment: SEC Form 4 filings show recent CEO and other insider sales (details & timing), which may weigh on sentiment until management commentary clarifies intent. SEC filing – CEO sale

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTRA. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Citigroup started coverage on Natera in a research report on Wednesday. They set a “buy” rating and a $300.00 target price on the stock. Guggenheim boosted their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday. Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Sixteen equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $238.89.

Natera Trading Up 2.3%

Shares of NASDAQ NTRA opened at $254.40 on Thursday. The stock has a market cap of $35.19 billion, a PE ratio of -111.09 and a beta of 1.62. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The company has a 50-day moving average of $225.41 and a 200 day moving average of $185.27.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period last year, the business earned ($0.26) earnings per share. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 3,848 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $229.08, for a total value of $881,499.84. Following the completion of the sale, the chief executive officer directly owned 136,568 shares of the company’s stock, valued at $31,284,997.44. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of Natera stock in a transaction on Monday, November 24th. The stock was sold at an average price of $236.12, for a total value of $17,709,000.00. Following the transaction, the director owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 343,280 shares of company stock worth $73,566,011 over the last quarter. Corporate insiders own 5.63% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.